Following its latest meeting, the EMA's CHMP has suggested granting marketing authorisation to seven medicines and extending the indications of 15 others.
List view / Grid view
Filter the results
A report has suggested that the drug price reforms in the US will affect AstraZeneca and Novartis negatively, but Novo could benefit.
The FDA has expanded the approved use of Lynparza to include the treatment of patients with metastatic breast cancer who have a BRCA gene mutation...
Lynparza has the potential to offer a new treatment option for patients with metastatic breast cancer...